Novartis' M&A Machine

M&A is competitive, and not all subjects are willing ones. Senior executives at Novartis, Big Pharma's number two acquirer, describe their system for identifying acquisition targets, understanding their priorities and walking away if prices get out of hand.

By Melanie Senior

With nearly $14 billion worth of acquisitions since 2005, Novartis AG has been the second-most aggressive shopper among Big Pharma....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By 

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Execs On The Move: May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.